5-(2,4-dihydroxy-5-propan-2-ylphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]-2,3-dihydro-1,2-oxazole-3-carboxamide

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 5-(2,4-dihydroxy-5-propan-2-ylphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]-2,3-dihydro-1,2-oxazole-3-carboxamide
• 化学式: C₂₆H₃₃N₃O₅
• 分子量: 467.6
• InChiKey: VJZQRLPIHJEADH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  34
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  103
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• ANTIBODY MOLECULES TO PD-1 AND USES THEREOF
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：EP3514179A1

  公开（公告）日：2019-07-24

  Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.

  本研究公开了与 PD-1 特异性结合的抗体分子。抗 PD-1 抗体分子可用于治疗、预防和/或诊断癌症或感染性疾病。
• ANTIBODY MOLECULES TO TIM-3 AND USES THEREOF
  申请人：Novartis AG

  公开号：EP3560959A1

  公开（公告）日：2019-10-30

  Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.

  本研究公开了与 TIM-3 特异性结合的抗体分子。抗 TIM-3 抗体分子可用于治疗、预防和/或诊断免疫、癌症或感染性疾病和/或失调。
• ANTIBODY MOLECULES TO LAG-3 AND USES THEREOF
  申请人：NOVARTIS AG

  公开号：EP3116909B1

  公开（公告）日：2019-11-13
• [EN] IDENTIFICATION, ASSESSMENT AND THERAPY OF ESSENTIAL THROMBOCYTHEMIA WITH RESISTANCE TO JAK2 INHIBITORS<br/>[FR] IDENTIFICATION, ÉVALUATION ET TRAITEMENT DE LA THROMBOCYTÉMIE ESSENTIELLE ASSOCIÉE À UNE RÉSISTANCE AUX INHIBITEURS DE JAK2
  申请人：ROUSSY INST GUSTAVE

  公开号：WO2014068072A1

  公开（公告）日：2014-05-08

  The inventors herein disclose mutations that naturally occur in the JAK2 gene sequence of human patients suffering from essential thrombocythemia and that confer resistance to commonly used JAK2 inhibitors and/or Hsp90 inhibitors. The present invention therefore relates to methods, compositions and kits aiming to detect the presence of these mutations so as to predict and try to overcome the patient resistance to treatment involving JAK2 inhibitors and/or Hsp90 inhibitors. Moreover, the invention describes a model to test new drugs and JAK2 inhibitors.